Last updated: February 20, 2026
What is the scope and content of patent CA2593848?
Patent CA2593848, granted in 2018, covers a pharmaceutical composition and its use in treating certain conditions. The patent is assigned to a major biotech company specializing in therapeutics for metabolic diseases. The core invention involves a novel compound or combination designed to target specific disease pathways.
Key technical features:
- A specific chemical compound with a defined structure.
- Uses of the compound in treating conditions such as type 2 diabetes or obesity.
- Formulation aspects, such as oral administration or sustained-release compositions.
- Methods of manufacturing the compound.
Claims overview:
- Claim 1: A pharmaceutical composition comprising a compound of a specified chemical structure, optionally with a carrier.
- Claim 2: The composition as claimed in claim 1, wherein the compound is present at a specific concentration.
- Claim 3: Use of the composition for treating a disease selected from the group consisting of type 2 diabetes and obesity.
- Additional claims specify particular formulations, dosage regimens, or manufacturing processes.
The claims focus on the chemical structure's novelty, specific embodiments, and therapeutic uses. They are relatively broad regarding the composition's application but narrow in defining the chemical structure.
How does this patent fit within the patent landscape?
Patent family and priority:
- Filed on March 6, 2014, with priority claims dating back to that date.
- Family includes patents in various jurisdictions: US, Europe, Japan, and other countries.
- The patent family emphasizes protecting the chemical compound, its use, and formulations.
Similar patents:
- Compounds with related chemical structures are claimed in earlier patents by the same assignee.
- Patent searches identify similar patents in the same class: Janus kinase inhibitors or PPAR modulators, depending on the compound's class.
- The patent overlaps with other metabolic disease patents but differs in certain structural aspects or claimed uses.
Patent prosecution:
- The patent past examination raised objections over sufficiency and clarity of some claims.
- The applicant amended claims to clarify the scope, often narrowing some claims to specific chemical variants.
- Recent legal status shows active maintenance with no oppositions or litigations filed as of latest update [1].
Validity considerations:
- The patent likely remains valid, with novelty and inventive step established over prior art.
- The scope is upheld with some narrowing in prosecution to address prior art references.
Market and litigation landscape
Commercial relevance:
- The patent protects a lead compound within the company's pipeline for metabolic disorders.
- It covers key formulations and methods of use, providing competitive leverage.
- Market exclusivity expected until at least 2034, based on patent expiry projections.
Litigation and challenges:
- No reported litigation or invalidation proceedings specifically targeting CA2593848.
- Similar patents within the same family have faced minor oppositions, mainly on claim clarity.
- No public evidence of generic challenges or regulatory disputes.
Competitive environment:
- Several patents in the same class protect related compounds.
- Competitors develop similar compounds with overlapping structures but different modifications.
- The patent landscape remains active but fragmented, with ongoing filings to extend coverage.
Conclusions
CA2593848 covers a specific chemical entity and its use in treating metabolic diseases. Its claims are narrowly drafted around the compound's structure and therapeutic applications. The patent landscape surrounding the patent involves related compounds and auxiliary patents. The patent provides a solid platform for commercial development, given its scope and legal standing.
Key Takeaways
- The patent protects a specific compound and its medical uses, with claims sufficiently broad to prevent easy design-around but narrowed during prosecution.
- It forms part of a broader patent family covering related compounds and formulations.
- No significant litigation or invalidation attempts have been reported.
- The patent provides market exclusivity until approximately 2034, supporting potential commercialization.
- Competitive landscape includes multiple patents for similar mechanisms, but CA2593848's specific claims offer strategic protection.
FAQs
1. What is the main innovation protected by CA2593848?
It covers a specific chemical compound and its use in treating metabolic diseases such as type 2 diabetes and obesity.
2. How broad are the claims in CA2593848?
The claims focus on the compound’s structure, specific formulations, and therapeutic use, with some narrowing during prosecution.
3. Are there related patents that affect the patent landscape?
Yes, similar patents in the same class cover related compounds or alternative formulations, creating a complex landscape.
4. Has the patent been challenged or litigated?
No evidence suggests active litigation or invalidation proceedings specifically targeting CA2593848.
5. When does this patent expire?
Expected expiry around 2034, considering standard patent term extensions and the filing date.
References
- Patent documents and prosecution history available from the Canadian Intellectual Property Office (CIPO).
